Jack A. Schalken

27.4k total citations · 3 hit papers
410 papers, 19.6k citations indexed

About

Jack A. Schalken is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Cancer Research. According to data from OpenAlex, Jack A. Schalken has authored 410 papers receiving a total of 19.6k indexed citations (citations by other indexed papers that have themselves been cited), including 202 papers in Pulmonary and Respiratory Medicine, 165 papers in Molecular Biology and 82 papers in Cancer Research. Recurrent topics in Jack A. Schalken's work include Prostate Cancer Treatment and Research (160 papers), Prostate Cancer Diagnosis and Treatment (94 papers) and Bladder and Urothelial Cancer Treatments (51 papers). Jack A. Schalken is often cited by papers focused on Prostate Cancer Treatment and Research (160 papers), Prostate Cancer Diagnosis and Treatment (94 papers) and Bladder and Urothelial Cancer Treatments (51 papers). Jack A. Schalken collaborates with scholars based in Netherlands, United States and Germany. Jack A. Schalken's co-authors include Gerald W. Verhaegh, F.M.J. Debruyne, Daphne Hessels, Herbert F.M. Karthaus, Marion J.G. Bussemakers, William B. Isaacs, Frank Smit, Tilly Aalders, Adrie van Bokhoven and J. Alfred Witjes and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nucleic Acids Research and Journal of Biological Chemistry.

In The Last Decade

Jack A. Schalken

406 papers receiving 19.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

DD3: a new prostate-specific gene, highly overexpressed in prostate cancer.

1999 809 citations Gerald W. Verhaegh, Frank Smit et al. profile →
DD3PCA3-based Molecular Urine Analysis for the Diagnosis of Prostate Cancer

2003 532 citations Inge M. van Oort, J. Alfred Witjes et al. profile →
Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer.

1992 514 citations Jack A. Schalken et al. profile →

Peers

Countries citing papers authored by Jack A. Schalken

Since Specialization

Citations

This map shows the geographic impact of Jack A. Schalken's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jack A. Schalken with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jack A. Schalken more than expected).

Fields of papers citing papers by Jack A. Schalken

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jack A. Schalken. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jack A. Schalken. The network helps show where Jack A. Schalken may publish in the future.

Co-authorship network of co-authors of Jack A. Schalken

This figure shows the co-authorship network connecting the top 25 collaborators of Jack A. Schalken. A scholar is included among the top collaborators of Jack A. Schalken based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jack A. Schalken. Jack A. Schalken is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A randomized phase II trial on the addition of dutasteride to combined androgen blockade therapy versus combined androgen blockade therapy alone in patients with advanced or metastatic salivary duct carcinoma – the DUCT study protocol 2024 ·BMC Cancer ·(unknown), Gerald W. Verhaegh, (unknown), Adriana C. H. van Engen–van Grunsven, C.M.L. Driessen, Nielka P. van Erp, Marianne A. Jonker, Jack A. Schalken, Carla M.L. van Herpen	1
2	Vaccination against Extracellular Vimentin for Treatment of Urothelial Cancer of the Bladder in Client-Owned Dogs 2023 ·Cancers ·(unknown), Judy R. van Beijnum, (unknown), (unknown), (unknown), Guy C. M. Grinwis, Jack A. Schalken, J. Alfred Witjes, Arjan W. Griffioen, Elisabeth J. M. Huijbers	7
3	Therapeutic biomarkers in metastatic castration-resistant prostate cancer: does the state matter? 2023 ·Critical Reviews in Clinical Laboratory Sciences ·(unknown), Sofie H. Tolmeijer, Niven Mehra, Jack A. Schalken	5
4	Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer 2023 ·Clinical Cancer Research ·Sofie H. Tolmeijer, (unknown), Takayuki Sumiyoshi, Edmond M. Kwan, Sarah W.S. Ng, Matti Annala, (unknown), Cameron Herberts, (unknown), Paul Hamberg, Diederik M. Somford, Inge M. van Oort, Jack A. Schalken, Niven Mehra, Nielka P. van Erp, Alexander W. Wyatt	26
5	Cross-Resistance between Platinum-Based Chemotherapy and PARP Inhibitors in Castration-Resistant Prostate Cancer 2023 ·Cancers ·(unknown), (unknown), Inge M. van Oort, Leonie I. Kroeze, Jack A. Schalken, Haiko J. Bloemendal, Niven Mehra	8
6	Early On-treatment Circulating Tumor DNA Measurements and Response to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer 2023 ·European Urology Oncology ·Sofie H. Tolmeijer, Sandra van Wilpe, Maartje J. Geerlings, Daniel von Rhein, Tineke J. Smilde, (unknown), Harm Westdorp, (unknown), Irma M. Oving, (unknown), Antoine G. van der Heijden, Tom Hofste, Marjan M. Weiss, Jack A. Schalken, Winald R. Gerritsen, Marjolijn J. L. Ligtenberg, Niven Mehra	10
7	Delivery of antisense oligonucleotides for splice‐correction of androgen receptor pre‐mRNA in castration‐resistant prostate cancer models using cell‐penetrating peptides 2022 ·The Prostate ·Maria Velez, (unknown), Gerald W. Verhaegh, Onno van Hooij, (unknown), Roland Brock, Jack A. Schalken	11
8	Liquid biopsy in bladder cancer: State of the art and future perspectives 2022 ·Critical Reviews in Oncology/Hematology ·Felice Crocetto, Biagio Barone, Matteo Ferro, Gian Maria Busetto, Evelina La Civita, Carlo Buonerba, Giuseppe Di Lorenzo, Daniela Terracciano, Jack A. Schalken	66
9	Impact of molecular tumour board discussion on targeted therapy allocation in advanced prostate cancer 2021 ·British Journal of Cancer ·(unknown), (unknown), Minke Smits, Inge M. van Oort, Winald R. Gerritsen, Jack A. Schalken, Marjolijn J. L. Ligtenberg, Katrien Grünberg, Leonie I. Kroeze, Haiko J. Bloemendal, Niven Mehra	9
10	Reovirus mutant jin-3 exhibits lytic and immune-stimulatory effects in preclinical human prostate cancer models 2021 ·Cancer Gene Therapy ·(unknown), Geertje van der Horst, Maaike H. van der Mark, (unknown), Diana J.M. van den Wollenberg, Corrina M.A. de Ridder, Debra Stuurman, Tilly Aalders, (unknown), Nadine van Montfoort, Wouter R. Karthaus, Niven Mehra, Minke Smits, Jack A. Schalken, Wytske M. van Weerden, Rob C. Hoeben, Gabri van der Pluijm	13
11	Plasma BRAF Mutation Detection for the Diagnostic and Monitoring Trajectory of Patients with LDH-High Stage IV Melanoma 2021 ·Cancers ·Sofie H. Tolmeijer, Rutger H.T. Koornstra, Jan Willem B. de Groot, Maartje J. Geerlings, (unknown), Marye J. Boers‐Sonderen, Jack A. Schalken, Winald R. Gerritsen, Marjolijn J. L. Ligtenberg, Niven Mehra	5
12	Impact of DNA damage repair defects and aggressive variant features on response to carboplatin‐based chemotherapy in metastatic castration‐resistant prostate cancer 2020 ·International Journal of Cancer ·(unknown), (unknown), Maarten J. van der Doelen, (unknown), (unknown), Hans M. Westgeest, Carin A. Uyl‐de Groot, (unknown), Marjolijn J. L. Ligtenberg, Inge M. van Oort, Winald R. Gerritsen, Jack A. Schalken, Leonie I. Kroeze, Haiko J. Bloemendal, Niven Mehra	26
13	Validation of a 2‐gene mRNA urine test for the detection of ≥GG2 prostate cancer in an opportunistic screening population 2020 ·The Prostate ·J. Rubio‐Briones, Ángel Borque‐Fernando, Luis Esteban, (unknown), (unknown), J. Casanova, Argimiro Collado, Carmen Mir, Á. Gómez-Ferrer, (unknown), (unknown), Ana Calatrava, José Antonio López‐Guerrero, Jack Groskopf, Jack A. Schalken, Wim Van Criekinge, José L. Domínguez-Escrig	8
14	Improving the barrier function of damaged cultured urothelium using chondroitin sulfate 2019 ·Neurourology and Urodynamics ·(unknown), Dick Janssen, Cornelius F.J. Jansen, Jack A. Schalken, John Heesakkers	13
15	miRNA-520f Reverses Epithelial-to-Mesenchymal Transition by Targeting ADAM9 and TGFBR2 2017 ·Cancer Research ·(unknown), Onno van Hooij, (unknown), Frank Smit, Paula I. van Noort, Iman J. Schultz, Roel Q.J. Schaapveld, Jack A. Schalken, Gerald W. Verhaegh	48
16	TMPRSS2 Fusions with Oncogenic ETS Factors in Prostate Cancer Involve Unbalanced Genomic Rearrangements and Are Associated with HDAC1 and Epigenetic Reprogramming 2006 ·Cancer Research ·Kristiina Iljin, Maija Wolf, Henrik Edgren, Santosh Gupta, Sami Kilpinen, Rolf I. Skotheim, Mari Peltola, Frank Smit, Gerald W. Verhaegh, Jack A. Schalken, Matthias Nees, Olli Kallioniemi	180
17	hTERT-Immortalized Prostate Epithelial and Stromal-Derived Cells: an Authentic In vitro Model for Differentiation and Carcinogenesis 2006 ·Cancer Research ·Ira Kogan, Naomi Goldfinger, Michael Milyavsky, Merav Cohen, Igor Shats, Gerhard Dobler, Helmut Klocker, Bohdan Wasylyk, Maureen Völler, Tilly Aalders, Jack A. Schalken, Moshe Oren, Varda Rotter	86
18	Intermediate Cells in Human Prostate Epithelium Are Enriched in Proliferative Inflammatory Atrophy 2003 ·American Journal Of Pathology ·Geert J.L.H. van Leenders, Wesley R. Gage, Jessica Hicks, (unknown), Tilly Aalders, Jack A. Schalken, Angelo M. De Marzo	143
19	Basic research in urological oncology 1996 ·KARGER eBooks ·L. Luciani, F.M.J. Debruyne, Jack A. Schalken	3
20	fur gene expression as a discriminating marker for small cell and nonsmall cell lung carcinomas. 1987 ·Journal of Clinical Investigation ·Jack A. Schalken, Anton Roebroek, (unknown), S S Wagenaar, F.M.J. Debruyne, Henri P.J. Bloemers, W J Van de Ven	136

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact